Should patients stop their biologic treatment during the COVID-19 pandemic

J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.

Authors

Arjun M Bashyam¹, Steven R Feldman^{1

2

3

4}

Affiliations

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
² Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
³ Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina.
⁴ Department of Dermatology, University of Southern Denmark, Odense, Denmark.

PMID: 32191143
DOI: 10.1080/09546634.2020.1742438

No abstract available

Publication types

Editorial

MeSH terms

Betacoronavirus
Biological Products / therapeutic use*
COVID-19
Coronavirus Infections / complications*
Humans
Pandemics
Pneumonia, Viral / complications*
Psoriasis / complications
Psoriasis / therapy*
SARS-CoV-2
Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

Biological Products
Tumor Necrosis Factor Inhibitors